Secondary Progressive Multiple Sclerosis (SPMS) - Market Insight, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Secondary Progressive Multiple Sclerosis (SPMS) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Secondary Progressive Multiple Sclerosis (SPMS) epidemiology and market outlook for the 7MM.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Secondary Progressive Multiple Sclerosis (SPMS) Understanding and Treatment Algorithm

The market report provides the overview of the Secondary Progressive Multiple Sclerosis (SPMS) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Secondary Progressive Multiple Sclerosis (SPMS) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Secondary Progressive Multiple Sclerosis (SPMS) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Secondary Progressive Multiple Sclerosis (SPMS) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Secondary Progressive Multiple Sclerosis (SPMS) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Secondary Progressive Multiple Sclerosis (SPMS) market.

Secondary Progressive Multiple Sclerosis (SPMS) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Secondary Progressive Multiple Sclerosis (SPMS) Report Insights

- Patient Population in Secondary Progressive Multiple Sclerosis (SPMS)

- Therapeutic Approaches in Secondary Progressive Multiple Sclerosis (SPMS)

- Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Analysis

- Secondary Progressive Multiple Sclerosis (SPMS) Market Size and Trends

- Secondary Progressive Multiple Sclerosis (SPMS) Market Opportunities

- Impact of upcoming Therapies in Secondary Progressive Multiple Sclerosis (SPMS)

Secondary Progressive Multiple Sclerosis (SPMS) Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Secondary Progressive Multiple Sclerosis (SPMS) Report Assessment

- Current Treatment Practices in Secondary Progressive Multiple Sclerosis (SPMS)

- Unmet Needs in Secondary Progressive Multiple Sclerosis (SPMS)

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Secondary Progressive Multiple Sclerosis (SPMS) market

- Organize sales and marketing efforts by identifying the best opportunities for Secondary Progressive Multiple Sclerosis (SPMS) market

- To understand the future market competition in the Secondary Progressive Multiple Sclerosis (SPMS) market.

Secondary Progressive Multiple Sclerosis (SPMS) - Market Insight, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Secondary Progressive Multiple Sclerosis (SPMS) Market Overview at a Glance
2.1. Market Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) in 2016
2.2. Market Share Distribution of Secondary Progressive Multiple Sclerosis (SPMS) in 2028
3. Disease Background and Overview: Secondary Progressive Multiple Sclerosis (SPMS)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
4.3. Total Prevalent Patient Population of Secondary Progressive Multiple Sclerosis (SPMS) in 7MM - By Countries
5. Epidemiology of Secondary Progressive Multiple Sclerosis (SPMS) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.1.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.1.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.1.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.1.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.4.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.4.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.4.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.4.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.5.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.5.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.5.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.6.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.6.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.6.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.7.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.7.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.7.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.8.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.8.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.8.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9.3. Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.9.4. Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) *
5.9.5. Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
5.9.6. Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Secondary Progressive Multiple Sclerosis (SPMS)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Secondary Progressive Multiple Sclerosis (SPMS)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Secondary Progressive Multiple Sclerosis (SPMS) : 7MM Market Analysis
12.1. 7MM Market Size of Secondary Progressive Multiple Sclerosis (SPMS)
12.2. 7MM Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS)
12.3. 7MM Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products
13. Secondary Progressive Multiple Sclerosis (SPMS) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in United States
13.1.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in United States
13.1.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in Germany
13.2.1.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in Germany
13.2.1.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in France
13.2.2.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in France
13.2.2.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in Italy
13.2.3.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in Italy
13.2.3.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in Spain
13.2.4.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in Spain
13.2.4.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in United Kingdom
13.2.5.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in Japan
13.3.2. Percentage Share of drugs marketed for Secondary Progressive Multiple Sclerosis (SPMS) in Japan
13.3.3. Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Table 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Table 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Table 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Table 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Table 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Table 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Table 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Table 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 7: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 12: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 16: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 17: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 22: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 27: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 32: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 37: Treatable Cases of the Secondary Progressive Multiple Sclerosis (SPMS) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Figure 42:7MM- Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Figure 45: United States-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Figure 48: Germany-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Figure 51: France-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Figure 54: Italy-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Figure 57: Spain-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Figure 60:UK-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Secondary Progressive Multiple Sclerosis (SPMS) in USD MM (2016-2028)
Figure 63: Japan-Market Share Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Secondary Progressive Multiple Sclerosis (SPMS) by Therapies in USD MM (2016-2028)

  • Global Fingolimod Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74
    The global Fingolimod market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Multiple Sclerosis Drugs Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The Multiple Sclerosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Sclerosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provi......
  • Global Multiple Sclerosis Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118
    Market Overview of Global Multiple Sclerosis market: According to our latest research, the global Multiple Sclerosis market looks promising in the next 5 years. As of 2022, the global Multiple Sclerosis market was estimated at USD 13809.22 million, and it's anticipated to reach USD 21672.55 million in 2028, with a CAGR of 7.8% during the forecast years. Multiple sclerosis (MS) is a chronic inflammatory neuropathy characterized by demyelination, axonal transection, and neurode......
  • Fingolimod - Global Market Insights and Sales Trends 2024
    Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 77
    The global Fingolimod market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Fingolimod in various end use industries. The expanding demands from the Medical Field, Science Research Field and Other Fields,, are propelling Fingolimod market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Inj......
  • Global Fingolimod Market Research Report 2023, Forecast to 2028
    Published: 19-Dec-2023        Price: US 2680 Onwards        Pages: 133
    Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......
  • Global Fingolimod Professional Survey Report 2023, Forecast to 2028
    Published: 19-Dec-2023        Price: US 3280 Onwards        Pages: 101
    Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......
  • Multiple Sclerosis Drugs - Global Market Insights and Sales Trends 2024
    Published: 19-Dec-2023        Price: US 3350 Onwards        Pages: 96
    This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Multiple Sclerosis Drugs, with both qu......
  • Global Multiple Sclerosis Drugs Market Research Report 2023
    Published: 25-Oct-2023        Price: US 2900 Onwards        Pages: 87
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Multiple Sclerosis Drugs market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Biogen - Sanofi - Novartis - Teva - Merck KGaA - Bayer - ACORDA - Mallinckrodt Segment by Type - Injectable......
  • Global Multiple Sclerosis Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 13-Jun-2023        Price: US 3260 Onwards        Pages: 122
    Multiple sclerosis (MS) is the most common disabling neurological disease in young people worldwide. The Multiple Sclerosis Drugs market revenue was 15099.44 Million USD in 2022, and will reach 23584.78 Million USD in 2028, with a CAGR of 7.72% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Multiple Sclerosis Drugs industry, and breaks down according to the type, application, and consumption area of Multiple Sclero......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs